CORVUS PHARMACEUTICALS INC. - COMMON STOCK

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

01 11 2023 19:31:53 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

31 10 2023 16:02:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

06 9 2023 16:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

08 8 2023 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

01 8 2023 08:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

06 7 2023 12:59:15 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

29 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

15 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

31 5 2023 08:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

17 5 2023 09:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

08 5 2023 16:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

20 4 2023 09:00:01 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

17 4 2023 09:00:01 提供 Nasdaq GlobeNewswire

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

03 4 2023 08:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

28 3 2023 16:02:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

21 3 2023 16:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

14 3 2023 16:35:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

21 2 2023 07:00:01 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

12 12 2022 10:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

05 12 2022 08:30:00 提供 Nasdaq GlobeNewswire